Demonstrates how miR-301b-3p reduces cisplatin sensitivity in breast cancer, suggesting new targets for treatment.
This study demonstrates that miR-301b-3p promotes BC proliferation and reduces cisplatin sensitivity by suppressing ALX4, a mechanism mediated through the regulation of DNA damage pathways. These findings offer new insights into cisplatin resistance and suggest potential therapeutic targets for overcoming chemoresistance in BC.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: